BIO
Bio-Rad Laboratories Inc
381.00$
-1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 51.4% | 47.9% | 47.9% | 46.3% | 36.1% | 27.2% | 16.5% | 11.2% | 23.4% | 24.8% | 32.4% | 27.5% | |
| 12.4% | 12.3% | 11.8% | 9.0% | 7.7% | 8.2% | 5.1% | 2.6% | 3.2% | 3.3% | 5.2% | 5.0% | |
| 20.9% | 21.2% | 21.8% | 17.7% | 15.1% | 13.9% | 7.6% | 4.9% | 13.3% | 13.1% | 17.8% | 14.6% | |
| 11.3% | 10.6% | 9.7% | 10.9% | 7.0% | 4.9% | 3.2% | 2.4% | 3.7% | 4.0% | 4.8% | 4.5% | |
| 14.1% | 13.2% | 13.6% | 13.9% | 10.4% | 6.9% | 4.8% | 3.2% | 5.3% | 6.3% | 8.1% | 7.0% | |
| 12.8% | 11.8% | 12.7% | 11.5% | 9.1% | 6.2% | 3.8% | 3.9% | 3.7% | 5.9% | 7.4% | 6.7% | |
| 15.0% | 13.4% | 12.4% | 11.8% | 3.9% | 3.3% | 2.3% | 2.0% | 3.0% | 3.4% | 4.4% | 5.5% | |
| 7.6% | 5.8% | 4.2% | 4.1% | 2.4% | 1.8% | 1.5% | 1.4% | 2.5% | 2.6% | 3.1% | 1.6% | |
| 34.6% | 32.9% | 33.0% | 31.4% | 28.3% | 28.1% | 23.8% | 23.1% | 28.8% | 28.9% | 29.8% | 29.5% | |
| 13.4% | 11.9% | 12.2% | 11.8% | 8.0% | 11.3% | 4.9% | 3.8% | 4.2% | 4.3% | 5.0% | 4.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 5.8% | 0.3% | 0.2% | 0.3% | 0.3% | 0.5% | 0.4% | |
| 3.8% | 3.3% | 3.5% | 3.2% | 2.2% | 1.3% | 1.1% | 0.8% | 1.0% | 1.2% | 1.3% | 1.2% | |
| 13.0% | 11.7% | 11.3% | 10.2% | 7.8% | 0.2% | 0.1% | 0.1% | 8.9% | 9.7% | 12.8% | 11.4% | |
| 65.4% | 67.1% | 67.0% | 68.6% | 71.7% | 71.9% | 76.2% | 76.9% | 71.2% | 71.1% | 70.2% | 70.5% | |
| 50.7% | 48.7% | 47.5% | 42.8% | 66.3% | 68.3% | 71.4% | 76.0% | 73.3% | 75.3% | 79.2% | 77.3% | |
| 0.9% | 0.8% | 0.8% | 0.7% | 0.5% | 0.4% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.